Phase I Dose Escalation Study to Determine the Safety and Pharmacokinetics of MSX-122 Administered Orally in Patients with Refractory Metastatic or Locally Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2010
At a glance
- Drugs Q 122 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 12 Mar 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 30 Nov 2007 New trial record.